BIA-ALCL explained: a patient's guide for 2026
BIA-ALCL (Breast Implant-Associated Anaplastic Large Cell Lymphoma) is a rare, treatable lymphoma associated almost exclusively with one type of macrotextured implant (Allergan Biocell, withdrawn in 2019). Risk with smooth or modern microtextured implants is extremely low or unmeasurable. Reported lifetime risk in textured-implant patients ranges from 1 in 2,200 to 1 in 86,000 — meaningful, but contextually low. Most cases present as delayed seroma 7–10 years after surgery and are highly curable when detected early. Modern practice (smooth or nanotextured implants, no-touch protocol) has effectively addressed the BIA-ALCL signal.
What is BIA-ALCL?
BIA-ALCL stands for Breast Implant-Associated Anaplastic Large Cell Lymphoma. It is a type of T-cell lymphoma — a cancer of the immune system — that develops in the fluid or scar tissue (capsule) immediately surrounding a breast implant. It is not a cancer of the breast itself.
Critically, BIA-ALCL is distinct from breast cancer. The two are unrelated. Breast augmentation does not increase breast cancer risk. BIA-ALCL is a separate, much rarer entity affecting the implant capsule.
The condition was first formally described in the 1990s and gained regulatory attention in the 2010s. By 2019, the connection to specific textured implants was clear enough that the FDA requested a market withdrawal of certain Allergan Biocell textured implants.
Why some implants and not others?
The BIA-ALCL signal is overwhelmingly tied to macrotextured implants — implants with a heavily roughened surface designed to grip surrounding tissue. The most-studied culprit is the Allergan Biocell texture, which used a salt-loss technique producing a deeply textured surface.
The leading hypothesis is that the macrotextured surface, in genetically susceptible patients, creates a chronic inflammatory environment in the implant capsule. Bacteria from the breast skin (notably Staphylococcus epidermidis) can colonise the textured surface as a biofilm, sustaining inflammation. Over years to decades, this chronic immune stimulation can — rarely — drive the development of an anaplastic T-cell lymphoma.
Implants associated with BIA-ALCL
- Allergan Biocell macrotextured implants — withdrawn from market in 2019 at FDA request
- Other macrotextured implants (Eurosilicone, Silimed) — also implicated to a lesser degree
Implants NOT associated
- Smooth-surface implants — risk is essentially unmeasurable
- Microtextured surfaces (e.g., Mentor Siltex) — no clear signal
- Nanotextured surfaces (e.g., Motiva SmoothSilk) — no signal
- Polyurethane-coated (Polytech Microthane) — no signal
How rare is BIA-ALCL?
The precise lifetime risk is debated because incidence depends on the implant population studied. Across published series:
- For Allergan Biocell macrotextured: reported lifetime risks range from 1 in 2,200 to 1 in 30,000
- For other textured implants: 1 in 30,000 to 1 in 86,000
- For smooth implants used alone (without prior textured implant exposure): no confirmed cases
Put in perspective:
- Lifetime risk of breast cancer in women: ~1 in 8
- Lifetime risk of being struck by lightning (US): ~1 in 15,300
- BIA-ALCL with macrotextured implant: 1 in 2,200–30,000
- BIA-ALCL with smooth implant: not established (presumed extremely rare or zero)
The number to remember: the great majority of breast augmentation patients — particularly those with smooth, microtextured, or nanotextured implants placed in the modern era — face a practically negligible BIA-ALCL risk. The historical signal traces almost entirely to one specific texture that has been withdrawn.
What are the symptoms?
BIA-ALCL most commonly presents as a delayed seroma — fluid accumulation around the implant — typically 7–10 years (sometimes longer) after the original surgery. Symptoms include:
- Sudden swelling of one breast (usually unilateral, not both)
- A new lump in the breast or armpit
- Pain or asymmetry that wasn't previously present
- Less commonly: skin rash, fever or systemic symptoms
Symptoms appearing years after surgery should always be evaluated. Early evaluation is the difference between a simple aspiration-and-cytology workup and a more involved one.
What does treatment look like?
BIA-ALCL detected at an early stage is highly curable. The standard treatment is:
- Surgery — removal of the implant and the surrounding capsule (en bloc capsulectomy). For most patients with localised BIA-ALCL, this is curative on its own.
- Pathology — fluid and capsule analysis confirms the diagnosis and stages the disease.
- Oncology evaluation — for advanced or invasive cases, which are rare; chemotherapy or radiation may be added.
Reported survival in early-stage BIA-ALCL exceeds 90% with appropriate surgical management. The treatment burden is significantly lower than for most other lymphomas.
Modern practice in 2026
The understanding of BIA-ALCL has reshaped breast augmentation practice over the past decade. Modern best practice — used in Dr. Erdal's clinic and most evidence-based aesthetic surgery practices — addresses the risk through:
Surface choice
Smooth, microtextured (Mentor Siltex), nanotextured (Motiva SmoothSilk) and polyurethane-coated (Polytech Microthane) options are all available. Macrotextured implants of the Biocell type are no longer used.
The "no-touch" surgical protocol
Originally described by Adams and Mladick, the no-touch technique includes:
- Antibiotic irrigation of the implant pocket
- Use of a Keller funnel (sterile delivery sleeve) so the implant never contacts the skin
- Nipple shielding to reduce bacterial transfer
- Sterile gloves changed before implant handling
Together these reduce the bacterial bioburden in the implant capsule — the central proposed driver of chronic inflammation.
Patient identification cards
Every patient receives a manufacturer-issued implant card with serial number, surface type, lot number and brand. This is your lifetime traceability — keep it permanently.
What does Dr. Erdal do?
In Dr. Erdal's practice:
- Implant choice is collaborative — patients select between Mentor (smooth or Siltex), Motiva (SmoothSilk nanotextured) and Polytech (POLYtxt or Microthane). Macrotextured implants of the Biocell type are not used.
- The no-touch protocol is standard — antibiotic irrigation, Keller funnel delivery, nipple shielding, sterile field discipline.
- Patients are informed of the BIA-ALCL signal during consultation and given written documentation. Patient autonomy and informed consent are foundational, not optional.
- Long-term follow-up is encouraged — including the ability to message via WhatsApp years after surgery if anything unusual develops.
Bottom line: If you're considering breast augmentation in 2026 with a board-certified surgeon, smooth/microtextured/nanotextured/polyurethane-coated implants and modern surgical protocol, your individual BIA-ALCL risk is exceptionally low. The risk profile is part of an evidence-based informed-consent conversation — not a reason to forgo a procedure many patients find life-changing.
Frequently asked questions
Personalised assessment in your own time
Send three photos via WhatsApp for an individualised technique recommendation, implant guidance and all-inclusive quote within 24 hours.
Message Dr. Erdal on WhatsApp